Company Research Report: Fabbrica Italiana Sintetici S.p.A. (FIS)

Company Overview

• Name: Fabbrica Italiana Sintetici S.p.A. (FIS)

• Mission: Not explicitly stated; however, FIS emphasizes sustainable, secure, and agile production, aiming to advance and preserve knowledge for future generations.

• Founded: 1957 by Giovanni Ferrari and his sons Antonio, Gianfranco, and Ottavio, along with key contributors such as Dr. Colbertaldo, Dr. Perlotto, and Mr. Caltran.

• Key People: No specific individuals currently highlighted beyond founders.

• Headquarters: Viale Milano, 26, 36075 Montecchio Maggiore, Vicenza, Italy.

• Number of Employees: Over 1800, including a significant portion in research and development.

• Revenue: No information is available.

• Known For: FIS is a leader in Europe in the production of active pharmaceutical ingredients (APIs) and intermediates for the pharmaceutical industry.

Products

Products Offered

1. Contract Development: Includes process development from conception through to validation.
2. Contract Manufacturing: Comprehensive production services for APIs, intermediates, and finished products.
3. Generic API Development & Manufacturing: Focus on various therapeutic areas such as central nervous system, antibacterials, anti-inflammatories, and more.
4. Veterinary APIs: Production for API veterinary businesses, including ecto- and endoparasiticides, antibiotics, and hormonal products.
5. Specialty Services: High explosion-proof units, sterile manufacturing, fluorination, etc.

Product Details

1. Generic APIs:

• Description: These include a wide range of APIs under various therapeutic categories.

• Key Features: Supported by strong regulatory expertise and intellectual property management.

2. Veterinary Products:

• Description: APIs for veterinary use with production facilities complying with multiple international standards.

• Key Features: End-to-end support from R&D to production and registration assistance.

3. CDMO Services:

• Description: Customized development and manufacturing services.

• Key Features: Integrated quality management and state-of-the-art facilities equipped with advanced technologies like spray drying and high-potency API manufacturing.

Recent Developments

• Recent Company Developments:

• In 2023, FIS was acquired by Bain Capital, a significant shift indicating potential growth and strategic alignment.

• Ongoing investments, such as the establishment of incinerator and finishing departments at Termoli and Montecchio respectively.

• New Products Launched: No explicit information provided.

• New Features Added:

• Expansion in high potent, sterile processes, and fluorination technology.

• The development and installation of kilolab facilities for HPAPI (Highly Potent Active Pharmaceutical Ingredient).

• New Partnerships: No specific partnerships mentioned.

Conclusion

FIS, with over six decades of experience, stands as a key player in API production, emphasizing sustainable practices and innovative research and development. Its comprehensive range of services and dedication to quality and compliance make it a reliable partner in the pharmaceutical industry.